Jecure Therapeutics
Jecure Therapeutics is a San Diego-based private biotech founded in 2016 that discovers therapeutics for non-alcoholic steatohepatitis (NASH), operating as a preclinical-stage drug discovery company with a $20M Series A led by Versant Ventures.
- Company typePrivate
- Founded2024
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Jecure Therapeutics does
Jecure Therapeutics is a privately-held, for-profit biotechnology company headquartered in San Diego, California, founded in 2016. The firm is focused exclusively on the discovery of innovative therapeutics for the treatment of non-alcoholic steatohepatitis (NASH), a chronic liver disease with high unmet medical need and a competitive therapeutic landscape. The company operates with a small team of 11-50 employees, consistent with an early-stage drug discovery profile.
Jecure's business activity centers on early-stage R&D in the metabolic liver disease space, targeting novel mechanisms relevant to NASH pathogenesis. As a preclinical-stage biotech, the company has raised a $20 million Series A financing round in January 2017 led by Versant Ventures, which would have been deployed toward medicinal chemistry, target validation, and IND-enabling work. No commercial products, licensing deals, partnerships, or revenue-generating collaborations are disclosed in the source material, indicating the company has been operating in a purely investment-funded discovery mode.
Jecure serves the broader biopharmaceutical market indirectly through the development of NASH therapeutic candidates intended for eventual out-licensing, partnership, or acquisition by larger pharma players. The firm has no direct end customers, no pricing model, no go-to-market sales motion, and no disclosed commercial revenue streams; the only documented external counterparty is its lead investor, Versant Ventures.
Jecure Therapeutics firmographics
Firmographics- Name
- Jecure Therapeutics
- Legal name
- Vsport胜利因您更精彩
- Website
- https://jecuretx.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Jecure Therapeutics is a San Diego-based private biotech founded in 2016 that discovers therapeutics for non-alcoholic steatohepatitis (NASH), operating as a preclinical-stage drug discovery company with a $20M Series A led by Versant Ventures.
- Ownership category
- akta.pro rank
Jecure Therapeutics industry classification
Industry- Product category
- NASH therapeutics drug discovery
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
- akta.pro secondary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where Jecure Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Jecure Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Research Project Funding: Government-funded research projects including National Natural Science Foundation projects, Hunan Province key research projects, and other provincial/ministerial level funding. In recent 3 years, total research funding exceeded 14 million RMB.
- Technology Transfer and Consulting Services: Transfer of research achievements including forest fire monitoring systems and remote sensing analysis platforms to government agencies like the Hunan Provincial Forest Fire Prevention Command Center. Also provides GIS and remote sensing technical training services.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Jecure Therapeutics product offering
Product offeringCore offering
Jecure Therapeutics is focused on the discovery of innovative therapeutics for the treatment of non-alcoholic steatohepatitis (NASH). The company conducts early-stage, preclinical research to identify and validate small-molecule drug candidates targeting metabolic liver disease pathways, with the goal of advancing these candidates toward pharmaceutical partnerships and clinical development.
Product overview
Based on the source data, this is an academic department (Vsport/胜利因您更精彩) at Central South University of Forestry and Technology, not a product company. The website describes an educational institution offering undergraduate programs in Geographic Information Science, Surveying Engineering, Remote Sensing Science and Technology, and Artificial Intelligence, as well as master's programs in Remote Sensing Science and Technology and Electronic Information (Artificial Intelligence). There are no commercial products or services described.
Differentiator
Problem solved
Functional benefit
Products and services
- Preclinical NASH therapeutic candidates Preclinical small-molecule drug candidates under discovery and optimization for the treatment of non-alcoholic steatohepatitis and related metabolic liver diseases. Intended to be out-licensed or partnered with large pharmaceutical companies for further clinical development and commercialization.
Quantifiable outcome
- Forest fire monitoring system deployed at provincial level in Hunan, being promoted nationwide
- +4 more outcomes
Companies that use Jecure Therapeutics
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles1 record
Jecure Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Jecure Therapeutics partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Anhui Tianlintai Technology Co., Ltd.coreEstablished industry-academia-research cooperation agreement in 2015. Jointly established polar-orbiting and geostationary meteorological satellite ground stations. The company serves as a production-education base for undergraduate talent training.
- Hunan Second Surveying and Mapping InstituteminorResearch exchange and collaboration in remote sensing technology applications. The institute serves as a reference for industry practices and provides potential employment opportunities for graduates.
- Hunan Province First and Third Surveying and Mapping InstituteminorIndustry-academia-research collaboration for student internship and employment opportunities. Provides platform for expanding employment channels for graduates.
- Huatec (华测导航)coreConducts teaching practical training on campus. Collaborates on UAV aerial survey technology demonstrations and technical discussions. Supports the college's practical teaching transformation.
- South Surveying Group (南方测绘集团)minorConducts campus recruitment activities. Provides employment opportunities for graduates in surveying and mapping industry.
- Guangtong Surveying CompanyminorConducts campus recruitment activities, hiring graduates for surveying positions.
- China Radio and Television Hunan Network Co., Ltd.minorCorporate visit and business exchange in July 2025. Explored cooperation opportunities in low-altitude economy, talent joint training, and collaborative scientific research.
- China Broadcasting Hunan Future Digital Technology BranchminorDiscussed cooperation in subtropical forest and grass digital twin innovation center platform construction.
- Central South University (地球科学与信息物理学院)minorResearch exchange on talent training program revision. Learning experiences in innovative talent cultivation, curriculum system construction, and intelligent teaching.
Scale indicators12 records
Recent moves2 records
Expansion highlights3 records
Jecure Therapeutics competitors and assessment
Company assessmentEmerging players
- Akero Therapeutics: Clinical-stage developer of FGF21 analogs for NASH/MASH; comparable as a venture-backed hepatology-focused biotech.
- Viking Therapeutics: Mid-stage clinical biotech pursuing metabolic disease therapies including NASH; comparable in clinical stage and therapeutic area overlap.
- Metsera: Emerging obesity/metabolic disease biotech with liver disease overlap; comparable as a discovery-stage peer tackling cardiometabolic indications adjacent to NASH.
Direct peers
- Intercept Pharmaceuticals: Pioneer in NASH/liver disease therapeutics (obeticholic acid); directly comparable as a focused hepatology drug developer targeting NASH fibrosis.
- NGM Biopharmaceuticals: Clinical-stage biotech with NASH and metabolic liver disease programs; small-cap hepatology-focused peer comparable in size and disease focus.
- Madrigal Pharmaceuticals: Developer of resmetirom, an approved NASH/MASH therapy; a direct competitor pursuing innovative therapeutics in the same NASH indication.
- Galmed Pharmaceuticals: Clinical-stage company developing therapeutics for liver, metabolic and inflammatory diseases including NASH, directly comparable in early/small-cap profile.
Broad incumbents
- Gilead Sciences (NASH efforts): Large pharma with significant NASH investment (e.g., simtuzumab, cilofexor programs); comparable as a major competitor in the same therapeutic area, with broader portfolio.
- Pfizer (NASH efforts): Large pharma with active NASH/MASH programs through partnerships and internal candidates; comparable as a deep-pocketed incumbent in the same indication.
- Novo Nordisk (NASH efforts): Global leader in metabolic disease with growing NASH franchise via GLP-1-based combinations; comparable as an incumbent whose diabetes/obesity drugs are directly reshaping the NASH treatment paradigm.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
Jecure Therapeutics social profiles
Digital presenceJecure Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Jecure Therapeutics leadership team
Management profileNumber of profiles
Jecure Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Jecure Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Jecure Therapeutics
What does Jecure Therapeutics do?
Jecure Therapeutics is focused on the discovery of innovative therapeutics for the treatment of non-alcoholic steatohepatitis (NASH). The company conducts early-stage, preclinical research to identify and validate small-molecule drug candidates targeting metabolic liver disease pathways, with the goal of advancing these candidates toward pharmaceutical partnerships and clinical development.
Is Jecure Therapeutics a public or private company?
Jecure Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Jecure Therapeutics founded?
Jecure Therapeutics was founded in 2024. It employs 11 to 50 people.
Where is Jecure Therapeutics based?
Jecure Therapeutics is headquartered in San Diego, United States, in the North America region.
How does Jecure Therapeutics make money?
Two revenue lines are on record. Research Project Funding is the primary driver. The others are technology Transfer and Consulting Services.
Who are Jecure Therapeutics's main competitors?
Emerging players on record are Akero Therapeutics, Viking Therapeutics and Metsera. Direct peers are Intercept Pharmaceuticals, NGM Biopharmaceuticals, Madrigal Pharmaceuticals and Galmed Pharmaceuticals. Broad incumbents are Gilead Sciences (NASH efforts), Pfizer (NASH efforts) and Novo Nordisk (NASH efforts).
Does Jecure Therapeutics have an API?
No public API is recorded for Jecure Therapeutics.
What industry is Jecure Therapeutics in?
Jecure Therapeutics's product category is NASH therapeutics drug discovery. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 32541 and its SIC code is 2834.